Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brolucizumab vs Aflibercept in Macular Edema Secondary to BRVO
NCT03802630Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 19
01
Overview
A Phase 3 trial of brolucizumab in macular edema, sponsored by Novartis. Started Jul 2019; status: terminated.
02
Drugs
brolucizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT03802630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802630.